University of California San Francisco

Flavio Vincenti - 144
Flavio
Vincenti
MD

Clinical Professor of Medicine and Surgery
Departments of Medicine and Surgery
Endowed Chair in Kidney Transplantation

Address

505 Parnassus Avenue, #M884D
San Francisco, CA 94117
United States

Email: [email protected]
Phone: 415-353-1322
Fax: 415-353-8974

ORCID: 0000-0002-6701-4680

Biography

I have been at UCSF since 1975 and on the faculty of the Department of Medicine in the division of Nephrology since 1976 and have been involved with the transplant service in patient care and clinical trials with novel immunosuppression drugs

Education

Institution Degree Dept or School End Date
University of California, San Francisco Residency School of Medicine

Board Certifications

American Board of Internal Medicine, Internal Medicine

American Board of Internal Medicine, Nephrology - Subspecialty

Clinical Expertise

Internal Medicine
Transplant Nephrology
Kidney Transplantation
Pancreas Transplantation
Living Kidney Donor Transplantation
End Stage Renal Disease (Kidney Failure)
Chronic Kidney Disease

Clinical Trials

  1. Immune Monitoring in Sensitized Patients at Risk of Rejection (NCT03794817)
    Related Conditions: End Stage Renal Disease, Kidney Disease| Start Date: | End Date:
  2. Tocilizumab for Renal Graft Inflammation (NCT02108600)
    Related Conditions: Kidney Transplant, Transplants| Start Date: | End Date:
  3. Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation (NCT02088931)
    Related Conditions: Kidney Transplant, Transplants, Immunotherapy| Start Date: | End Date:
  4. NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients (NCT01771705)
    Related Conditions: Kidney Transplant, Transplants| Start Date: | End Date:
  5. Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells (NCT00777400)
    Related Conditions: Autoimmune Disease, Kidney Transplant| Start Date: | End Date:
  6. Daratumumab and Belatacept for Desensitization (NCT04827979)
    Related Conditions: Kidney Transplant, Transplants| Start Date: | End Date:
  7. Belatacept to Prevent Organ Rejection in Kidney Transplant Patients (NCT00346151)
    Related Conditions: Kidney Transplant, Transplants| Start Date: | End Date:
  8. Treg Modulation With CD28 and IL-6 Receptor Antagonists (NCT04066114)
    Related Conditions: Kidney Transplant, Transplants| Start Date: | End Date:
  9. The Effect of Rituximab on the Development of Anti-Donor Antibodies (NCT00695097)
    Related Conditions: Kidney Transplant, Transplants| Start Date: | End Date:
  10. Precision Medicine Offers Belatacept Monotherapy (NCT02939365)
    Related Conditions: Transplants| Start Date: | End Date:
  11. Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) (NCT03443869)
    Related Conditions: Cytomegalovirus, Human Cytomegalovirus, Kidney Transplant, Transplants| Start Date: | End Date:
  12. Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants (NCT03363945)
    Related Conditions: Kidney Transplant, Transplants, Immunotherapy| Start Date: | End Date:
  13. Treg Therapy in Subclinical Inflammation in Kidney Transplantation (NCT02711826)
    Related Conditions: Kidney Transplant, Transplants| Start Date: | End Date:

In the News

Drug Provides Better Kidney Transplant Survival Rates Than Current Standard Of Care
January, 28, 2016 | UCSF Transplant Surgery
Toward Personalized Medicine for Kidney Transplant Recipients
August, 27, 2014 | UCSF Transplant Surgery

Grants and Funding

  • Applying precision MEdicine to optimize desensitization with noveL bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE) | NIH | 2014-07-01 - 2024-05-31 | Role: Principal Investigator
  • General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator

Research Interests

Transplant Nephrology

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 276
  1. The hepatocyte growth factor mimetic, ANG-3777, in kidney transplant recipients with delayed graft function: Results from a randomized phase 3 trial.
    Vincenti F, Bromberg J, Kim J, Faravardeh A, Leca N, Alperovich G, Csomor PA, Aslam S, Neylan J| | View in PubMed
  2. Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant.
    Vincenti F, Bestard O, Brar A, Cruzado JM, Seron D, Gaber AO, Ali N, Tambur AR, Lee H, Abbadessa G, Paul JA, Dudek M, Siegel RJ, Torija A, Semiond D, Lépine L, Ternes N, Montgomery RA, Stegall M| | View in PubMed
  3. State of the art in childhood nephrotic syndrome: concrete discoveries and unmet needs.
    Vincenti F, Angeletti A, Ghiggeri GM| | View in PubMed
  4. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
    Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA| | View in PubMed
  5. Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses.
    Duan M, Nguyen DC, Joyner CJ, Saney CL, Tipton CM, Andrews J, Lonial S, Kim C, Hentenaar I, Kosters A, Ghosn E, Jackson A, Knechtle S, Maruthamuthu S, Chandran S, Martin T, Rajalingam R, Vincenti F, Breeden C, Sanz I, Gibson G, Lee FE| | View in PubMed
  6. Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet.
    Vincenti F, Budde K, Grinyo J, Rostaing L, Kirk AD, Larsen CP| | View in PubMed
  7. Race-free estimated glomerular filtration rate equation in kidney transplant recipients: development and validation study.
    Raynaud M, Al-Awadhi S, Juric I, Divard G, Lombardi Y, Basic-Jukic N, Aubert O, Dubourg L, Masson I, Mariat C, Prié D, Pernin V, Le Quintrec M, Larson TS, Stegall MD, Bikbov B, Ruggenenti P, Mesnard L, Ibrahim HN, Nielsen MB, Matas AJ, Nankivell BJ, Benjamens S, Pol RA, Bakker SJL, Jouven X, Legendre C, Kamar N, Smith BH, Wadei HM, Durrbach A, Vincenti F, Remuzzi G, Lefaucheur C, Bentall AJ, Loupy A| | View in PubMed
  8. Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors.
    Rashmi P, Sigdel TK, Rychkov D, Damm I, Da Silva AA, Vincenti F, Lourenco AL, Craik CS, Reiser J, Sarwal MM| | View in PubMed
  9. Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell Analyses.
    Duan M, Nguyen DC, Joyner CJ, Saney CL, Tipton CM, Andrews J, Lonial S, Kim C, Hentenaar I, Kosters A, Ghosn E, Jackson A, Knechtle S, Maruthamuthu S, Chandran S, Martin T, Rajalingam R, Vincenti F, Breeden C, Sanz I, Gibson G, Eun-Hyung Lee F| | View in PubMed
  10. Burden of neutropenia and leukopenia among adult kidney transplant recipients: A systematic literature review of observational studies.
    Raval AD, Kistler KD, Tang Y, Vincenti F| | View in PubMed
  11. Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients.
    Looney CM, Schroeder A, Tavares E, Garg J, Schindler T, Vincenti F, Redfield RR, Jordan SC, Busque S, Woodle ES, Khan J, Eastham J, Micallef S, Austin CD, Morimoto A| | View in PubMed
  12. Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial.
    Hricik DE, Armstrong B, Alhamad T, Brennan DC, Bromberg JS, Bunnapradist S, Chandran S, Fairchild RL, Foley DP, Formica R, Gibson IW, Kesler K, Kim SJ, Mannon RB, Menon MC, Newell KA, Nickerson P, Odim J, Poggio ED, Sung R, Shapiro R, Tinckam K, Vincenti F, Heeger PS| | View in PubMed
  13. Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia.
    Brar S, Berry R, Raval AD, Tang Y, Vincenti F, Skartsis N| | View in PubMed
  14. IL-6 and TNFα Drive Extensive Proliferation of Human Tregs Without Compromising Their Lineage Stability or Function.
    Skartsis N, Peng Y, Ferreira LMR, Nguyen V, Ronin E, Muller YD, Vincenti F, Tang Q| | View in PubMed
  15. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
    Budde K, Prashar R, Haller H, Rial MC, Kamar N, Agarwal A, de Fijter JW, Rostaing L, Berger SP, Djamali A, Leca N, Allamassey L, Gao S, Polinsky M, Vincenti F| | View in PubMed
  16. Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study.
    Aubert O, Divard G, Pascual J, Oppenheimer F, Sommerer C, Citterio F, Tedesco H, Chadban S, Henry M, Vincenti F, Srinivas T, Watarai Y, Legendre C, Bernhardt P, Loupy A| | View in PubMed
  17. Tests for the noninvasive diagnosis of kidney transplant rejection should be evaluated by kidney transplant programs.
    Danovitch GM, Bunnapradist S, Cohen D, Hariharan S, McKay D, Ratner L, Stegall MD, Steiner RW, Stock PG, Vincenti F| | View in PubMed
  18. A Comparison of Ex Vivo Expanded Human Regulatory T Cells Using Allogeneic Stimulated B Cells or Monocyte-Derived Dendritic Cells.
    Lee LM, Zhang H, Lee K, Liang H, Merleev A, Vincenti F, Maverakis E, Thomson AW, Tang Q| | View in PubMed
  19. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial.
    Chandran S, Leung J, Hu C, Laszik ZG, Tang Q, Vincenti FG| | View in PubMed
  20. Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation.
    Zarinsefat A, Hartoularos G, Rychkov D, Rashmi P, Chandran S, Vincenti F, Yee CJ, Sarwal MM| | View in PubMed
  21. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
    Kirk AD, Adams AB, Durrbach A, Ford ML, Hildeman DA, Larsen CP, Vincenti F, Wojciechowski D, Woodle ES| | View in PubMed
  22. Phase 3 trial Design of the Hepatocyte Growth Factor Mimetic ANG-3777 in Renal Transplant Recipients With Delayed Graft Function.
    Vincenti F, Kim J, Gouveia D, Pelle G, Mayne TJ, Neylan JF| | View in PubMed
  23. The impact of belatacept on the phenotypic heterogeneity of renal T cell-mediated alloimmune response: The critical role of maintenance treatment and inflammatory load.
    Dobi D, Vincenti F, Chandran S, Greenland JR, Bowman C, Chen A, Junger H, Laszik ZG| | View in PubMed
  24. Single-cell RNA sequencing of Tocilizumab-treated peripheral blood mononuclear cells as an in vitro model of inflammation.
    Zarinsefat A, Hartoularos G, Chandran S, Yee CJ, Vincenti F, Sarwal MM| | View in PubMed
  25. A urine score for noninvasive accurate diagnosis and prediction of kidney transplant rejection.
    Yang JYC, Sarwal RD, Sigdel TK, Damm I, Rosenbaum B, Liberto JM, Chan-On C, Arreola-Guerra JM, Alberu J, Vincenti F, Sarwal MM| | View in PubMed
  26. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
    Harel E, Shoji J, Abraham V, Miller L, Laszik ZG, King A, Dobi D, Szabo G, Hann B, Sarwal MM, Craik CS, Vincenti F| | View in PubMed
  27. Assessment of 19 Genes and Validation of CRM Gene Panel for Quantitative Transcriptional Analysis of Molecular Rejection and Inflammation in Archival Kidney Transplant Biopsies.
    Sigdel T, Nguyen M, Liberto J, Dobi D, Junger H, Vincenti F, Laszik Z, Sarwal MM| | View in PubMed
  28. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation.
    Vincenti F, Klintmalm G, Yang H, Ram Peddi V, Blahunka P, Conkle A, Santos V, Holman J| | View in PubMed
  29. Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients.
    Pascual J, Berger SP, Chadban SJ, Citterio F, Kamar N, Hesselink DA, Legendre C, Eisenberger U, Oppenheimer F, Russ GR, Sommerer C, Rigotti P, Srinivas TR, Watarai Y, Henry ML, Vincenti F, Tedesco-Silva H| | View in PubMed
  30. Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.
    Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA, Formica R, Schindler T, Tran H, Looney C, Jamois C, Green C, Morimoto A, Rajwanshi R, Schroeder A, Cascino MD, Brunetta P, Borie D| | View in PubMed
  31. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J, TRANSFORM investigators| | View in PubMed
  32. Characterizing pre-transplant and post-transplant kidney rejection risk by B cell immune repertoire sequencing.
    Pineda S, Sigdel TK, Liberto JM, Vincenti F, Sirota M, Sarwal MM| | View in PubMed
  33. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
    Harel E, Shoji J, Abraham V, Miller L, Laszik Z, Thurison T, King A, Olshen A, Leung J, Szabo G, Hann B, Høyer-Hansen G, Craik CS, Vincenti F| | View in PubMed
  34. Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial.
    Busque S, Vincenti FG, Tedesco Silva H, O'Connell PJ, Yoshida A, Friedewald JJ, Steinberg SM, Budde K, Broeders EN, Kim YS, Hahn CM, Li H, Chan G| | View in PubMed
  35. Nuclear Factor of Activated T Cell-regulated Cytokine Gene Expression for Adjustment of Tacrolimus in Kidney Transplant Recipients: A Randomized Controlled Pilot Trial.
    Webber AB, Tatapudi V, Maw TT, Peralta C, Leung JCY, Vincenti F| | View in PubMed
  36. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.
    Vincenti F, Budde K, Merville P, Shihab F, Ram Peddi V, Shah M, Wyburn K, Cassuto-Viguier E, Weidemann A, Lee M, Flegel T, Erdman J, Wang X, Lademacher C| | View in PubMed
  37. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
    Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F, TRANSFORM Investigators| | View in PubMed
  38. Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.
    Florman S, Vincenti F, Durrbach A, Abouljoud M, Bresnahan B, Garcia VD, Mulloy L, Rice K, Rostaing L, Zayas C, Calderon K, Meier-Kriesche U, Polinsky M, Yang L, Medina Pestana J, Larsen CP| | View in PubMed
  39. Targeted Transcriptional Profiling of Kidney Transplant Biopsies.
    Sigdel TK, Nguyen M, Dobi D, Hsieh SC, Liberto JM, Vincenti F, Sarwal MM, Laszik Z| | View in PubMed
  40. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients.
    Wojciechowski D, Chandran S, Webber A, Hirose R, Vincenti F| | View in PubMed
  41. Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.
    Vincenti F, Blancho G, Durrbach A, Grannas G, Grinyó J, Meier-Kriesche HU, Polinsky M, Yang L, Larsen CP| | View in PubMed
  42. Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants.
    Chandran S, Tang Q, Sarwal M, Laszik ZG, Putnam AL, Lee K, Leung J, Nguyen V, Sigdel T, Tavares EC, Yang JYC, Hellerstein M, Fitch M, Bluestone JA, Vincenti F| | View in PubMed
  43. Retrospective evaluation of the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: A single-center clinical experience.
    Wojciechowski D, Chandran S, Yang JYC, Sarwal MM, Vincenti F| | View in PubMed
  44. Transplant trials with Tregs: perils and promises.
    Tang Q, Vincenti F| | View in PubMed
  45. B Cell Receptor Genes Associated With Tolerance Identify a Cohort of Immunosuppressed Patients With Improved Renal Allograft Graft Function.
    Asare A, Kanaparthi S, Lim N, Phippard D, Vincenti F, Friedewald J, Pavlakis M, Poggio E, Heeger P, Mannon R, Burrell BE, Morrison Y, Bridges N, Sanz I, Chandraker A, Newell KA, Turka LA| | View in PubMed
  46. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.
    Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J, Focal Segmental Glomerulosclerosis Study Group| | View in PubMed
  47. Belatacept: the challenges with transformational drugs.
    Vincenti F| | View in PubMed
  48. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
    Wojciechowski D, Chandran S, Vincenti F| | View in PubMed
  49. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N| | View in PubMed
  50. Current status of costimulatory blockade in renal transplantation.
    Wojciechowski D, Vincenti F| | View in PubMed
  51. Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2.
    Wojciechowski D, Vincenti F| | View in PubMed
  52. Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials.
    Klintmalm GB, Vincenti F, Kirk A| | View in PubMed
  53. Belatacept and Long-Term Outcomes in Kidney Transplantation.
    Vincenti F| | View in PubMed
  54. An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
    Webber AB, Vincenti F| | View in PubMed
  55. Belatacept and Long-Term Outcomes in Kidney Transplantation.
    Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP| | View in PubMed
  56. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.
    Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H, Yue S, Vincenti F| | View in PubMed
  57. A Computational Gene Expression Score for Predicting Immune Injury in Renal Allografts.
    Sigdel TK, Bestard O, Tran TQ, Hsieh SC, Roedder S, Damm I, Vincenti F, Sarwal MM| | View in PubMed
  58. Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients.
    Vincenti F, Silva HT, Busque S, O'Connell PJ, Russ G, Budde K, Yoshida A, Tortorici MA, Lamba M, Lawendy N, Wang W, Chan G| | View in PubMed
  59. The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study.
    Roedder S, Sigdel T, Salomonis N, Hsieh S, Dai H, Bestard O, Metes D, Zeevi A, Zeevi A, Gritsch A, Cheeseman J, Macedo C, Peddy R, Medeiros M, Vincenti F, Asher N, Salvatierra O, Shapiro R, Kirk A, Reed EF, Reed E, Sarwal MM| | View in PubMed
  60. Role of podocyte B7-1 in diabetic nephropathy.
    Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, D'Addio F, Chin M, Tezza S, Ben Nasr M, Mattinzoli D, Ikehata M, Corradi D, Schumacher V, Buvall L, Yu CC, Chang JM, La Rosa S, Finzi G, Solini A, Vincenti F, Rastaldi MP, Reiser J, Krolewski AS, Mundel PH, Sayegh MH| | View in PubMed
  61. Clinical aspects: focusing on key unique organ-specific issues of renal transplantation.
    Chandran S, Vincenti F| | View in PubMed
  62. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.
    Rostaing L, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S, Gang S, Gaite LE, Moal MC, Mondragón-Ramirez GA, Kothari J, Pupim L, Larsen CP| | View in PubMed
  63. Tofacitinib in kidney transplantation.
    Wojciechowski D, Vincenti F| | View in PubMed
  64. Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma.
    van Gelder T, Baan C, Vincenti F, Mannon RB| | View in PubMed
  65. Native renal function after combined liver-kidney transplant for type 1 hepatorenal syndrome: initial report on the use of postoperative Technetium-99 m-mercaptoacetyltriglycine scans.
    Vagefi PA, Qian JJ, Carlson DM, Aparici CM, Hirose R, Vincenti F, Wojciechowski D| | View in PubMed
  66. Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year.
    Wojciechowski D, Chanda R, Chandran S, Lee B, Webber A, Macaraig M, Tomlanovich S, Vincenti F| | View in PubMed
  67. Belatacept in kidney transplantation.
    Wojciechowski D, Vincenti F| | View in PubMed
  68. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study.
    Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, Scheuermann EH, Klinger M, Russ G, Pescovitz MD, Prestele H| | View in PubMed
  69. Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update.
    Wojciechowski D, Vincenti F| | View in PubMed
  70. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients.
    Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F| | View in PubMed
  71. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study.
    Grinyo J, Alberu J, Contieri FL, Manfro RC, Mondragon G, Nainan G, Rial Mdel C, Steinberg S, Vincenti F, Dong Y, Thomas D, Kamar N| | View in PubMed
  72. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.
    Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, Weimar W, Kim YS, Lawendy N, Lan SP, Kudlacz E, Krishnaswami S, Chan G| | View in PubMed
  73. Are calcineurin inhibitors-free regimens ready for prime time?
    Vincenti F| | View in PubMed
  74. Beyond belatacept: praise and progress for the FDA.
    Vincenti F| | View in PubMed
  75. Targeting JAK3 in kidney transplantation: current status and future options.
    Wojciechowski D, Vincenti F| | View in PubMed
  76. C4d/CD34 double-immunofluorescence staining of renal allograft biopsies for assessing peritubular capillary C4d positivity.
    Jen KY, Nguyen TB, Vincenti FG, Laszik ZG| | View in PubMed
  77. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.
    Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B| | View in PubMed
  78. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.
    Rostaing L, Neumayer HH, Reyes-Acevedo R, Bresnahan B, Florman S, Vitko S, Heifets M, Xing J, Thomas D, Vincenti F| | View in PubMed
  79. Belatacept.
    Vincenti F, Dritselis A, Kirkpatrick P| | View in PubMed
  80. Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation.
    Wojciechowski D, Vincenti F| | View in PubMed
  81. Novel strategies in immunosuppression: issues in perspective.
    Webber A, Hirose R, Vincenti F| | View in PubMed
  82. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
    Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F| | View in PubMed
  83. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients.
    Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, Nicholson M, Wahlberg J, Wissing KM, Abrams K, Witte S, Woodle ES| | View in PubMed
  84. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.
    Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F| | View in PubMed
  85. Response to questions regarding the design and results of the IMPACT trial.
    Humar A, IMPACT Investigators Steering Committee, Peeters P, Abramowicz D, Humar A, Lebranchu Y, Hauser I, Jardine A, Limaye AP, Vincenti F, Punch JD, Blumberg E| | View in PubMed
  86. An integrated safety profile analysis of belatacept in kidney transplant recipients.
    Grinyó J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP| | View in PubMed
  87. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
    Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B| | View in PubMed
  88. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study.
    Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P| | View in PubMed
  89. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade.
    Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG| | View in PubMed
  90. How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept.
    Wojciechowski D, Vincenti F| | View in PubMed
  91. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
    Ferguson R, Grinyó J, Vincenti F, Kaufman DB, Woodle ES, Marder BA, Citterio F, Marks WH, Agarwal M, Wu D, Dong Y, Garg P| | View in PubMed
  92. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
    Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, Steinberg S, Vincenti F, Shi R, Di Russo G, Thomas D, Grinyó J| | View in PubMed
  93. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database.
    Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S| | View in PubMed
  94. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.
    Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG| | View in PubMed
  95. Five-year safety and efficacy of belatacept in renal transplantation.
    Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, Klempnauer J, Lang P, Larsen CP, Mühlbacher F, Nashan B, Soulillou JP, Vanrenterghem Y, Wekerle T, Agarwal M, Gujrathi S, Shen J, Shi R, Townsend R, Charpentier B| | View in PubMed
  96. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P| | View in PubMed
  97. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).
    Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyó J| | View in PubMed
  98. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
    Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP| | View in PubMed
  99. Kidney transplantation at UCSF: 8,300 transplants and onward.
    Wojciechowski D, Hirose R, Stock P, Vincenti F, Baxter-Lowe LA, Salvatierra O| | View in PubMed
  100. Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases.
    Vincenti F, Cohen SD, Appel G| | View in PubMed
  101. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary.
    Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Wagner M, Balk EM, Kidney Disease: Improving Global Outcomes| | View in PubMed
  102. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients.
    Busque S, Leventhal J, Brennan DC, Steinberg S, Klintmalm G, Shah T, Mulgaonkar S, Bromberg JS, Vincenti F, Hariharan S, Slakey D, Peddi VR, Fisher RA, Lawendy N, Wang C, Chan G| | View in PubMed
  103. Kidney transplantation: the ideal immunosuppression regimen.
    Yabu JM, Vincenti F| | View in PubMed
  104. Transplantation: To convert or not to convert: lessons from the CONVERT trial.
    Bunnapradist S, Vincenti F| | View in PubMed
  105. The AST's perspective on the proposed kidney allocation system.
    Murphy B, Vincenti F, Meier-Kriesche HU| | View in PubMed
  106. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study.
    Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H, Daloze P| | View in PubMed
  107. Long-term renal function and cardiovascular disease risk in obese kidney donors.
    Tavakol MM, Vincenti FG, Assadi H, Frederick MJ, Tomlanovich SJ, Roberts JP, Posselt AM| | View in PubMed
  108. Evolving trends in induction therapy.
    Arias M, Campistol JM, Vincenti F| | View in PubMed
  109. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.
    Latek R, Fleener C, Lamian V, Kulbokas E, Davis PM, Suchard SJ, Curran M, Vincenti F, Townsend R| | View in PubMed
  110. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
    Kuypers DR, Ekberg H, Grinyó J, Nashan B, Vincenti F, Snell P, Mamelok RD, Bouw RM| | View in PubMed
  111. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation.
    Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F| | View in PubMed
  112. What's next in the pipeline.
    Vincenti F, Kirk AD| | View in PubMed
  113. Tolerance versus immunosuppression: a perspective.
    Halloran PF, Bromberg J, Kaplan B, Vincenti F| | View in PubMed
  114. Association of four DNA polymorphisms with acute rejection after kidney transplantation.
    Grinyó J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, Rashford M, Nasmyth-Miller C, Voulgari A, Spleiss O, Truman M, Essioux L| | View in PubMed
  115. Open letter to the FDA: new drug trials must be relevant.
    Vincenti F, Klintmalm G, Halloran PF| | View in PubMed
  116. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients.
    Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J, FREEDOM Study Group| | View in PubMed
  117. Costimulation blockade in autoimmunity and transplantation.
    Vincenti F| | View in PubMed
  118. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 7, 560-570, 2007.
    Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M, CAESAR study group| | View in PubMed
  119. Proteomics of plasma and urine in primary nephrotic syndrome in children.
    Candiano G, Musante L, Petretto A, Bruschi M, Santucci L, Urbani A, Scolari F, Gusmano R, Carraro M, Zennaro C, Vincenti F, Ghiggeri GM| | View in PubMed
  120. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7 1506-1514, 2007.
    Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Viecek A, Chadban S, El-Shahawy M, Budde K, Goto N, DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C2 Monitoring Versus Tacrolimus) inve| | View in PubMed
  121. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis.
    Yabu JM, Ho B, Scandling JD, Vincenti F| | View in PubMed
  122. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation.
    Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, Laskow D, Slakey DP, Lorber MI, Garg JP, Garovoy M| | View in PubMed
  123. Novel immunosuppression: small molecules and biologics.
    Yabu JM, Vincenti F| | View in PubMed
  124. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients.
    Pescovitz MD, Vincenti F, Hart M, Melton L, Whelchel J, Mulgaonkar S, McKay D, Leung M, Calleja E, Bouw MR| | View in PubMed
  125. Costimulation blockade--what will the future bring?
    Vincenti F| | View in PubMed
  126. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.
    Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N, DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Inves| | View in PubMed
  127. Sirolimus: defining nephrotoxicity in the renal transplant recipient.
    Tomlanovich SJ, Vincenti F| | View in PubMed
  128. Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albumin.
    Musante L, Candiano G, Petretto A, Bruschi M, Dimasi N, Caridi G, Pavone B, Del Boccio P, Galliano M, Urbani A, Scolari F, Vincenti F, Ghiggeri GM| | View in PubMed
  129. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.
    Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M| | View in PubMed
  130. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation.
    Vincenti F, Luggen M| | View in PubMed
  131. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature.
    Arns W, Cibrik DM, Walker RG, Mourad G, Budde K, Mueller EA, Vincenti F| | View in PubMed
  132. Living donor kidney transplant recipients and clinical trials: participation profiles and impact on post-transplant care.
    Brennan TV, Fuller TF, Vincenti F, Chan S, Chang CK, Bostrom A, Zlatunich JK, Tomlanovich SJ, Feng S| | View in PubMed
  133. Immunosuppression: today, tomorrow, and withdrawal.
    Hirose R, Vincenti F| | View in PubMed
  134. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.
    Vincenti F, de Andrés A, Becker T, Choukroun G, Cole E, González-Posada JM, Kumar MA, Moore R, Nadalin S, Nashan B, Rostaing L, Saito K, Yoshimura N| | View in PubMed
  135. Antibodies come back to the forefront in transplantation.
    Vincenti F| | View in PubMed
  136. A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients.
    Vincenti F, Mendez R, Curtis J, Light J, Pearson T, Wu YM, Katz SM, Akalin E, Esterl R, Gugliuzza K, Shihab F, Jordan S, Jonsson J, Molmenti E, Barbeito R| | View in PubMed
  137. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation.
    Land W, Vincenti F| | View in PubMed
  138. Current use and future trends in induction therapy.
    Vincenti F| | View in PubMed
  139. Rapidly developing nephrocalcinosis in a patient with end-stage liver disease who received a domino liver transplant from a patient with known congenital oxalosis.
    Aziz S, Callen PW, Vincenti F, Hirose R| | View in PubMed
  140. Costimulation blockade with belatacept in renal transplantation.
    Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B, Belatacept Study Group| | View in PubMed
  141. A drug of the past, a lesson for the future.
    Vincenti F| | View in PubMed
  142. Guidelines for the treatment and management of new-onset diabetes after transplantation.
    Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa JV, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M| | View in PubMed
  143. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis.
    Vincenti F, Ghiggeri GM| | View in PubMed
  144. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation.
    Vincenti F, Tuncer M, Castagneto M, Klinger M, Friman S, Scheuermann EH, Wiecek A, Russ GR, Martinek A, Nonnast-Daniel B, DIRECT Study Group| | View in PubMed
  145. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
    Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlethwaite JR, Vincenti F, Cohen DJ| | View in PubMed
  146. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation.
    Vincenti F, Rostaing L, DIRECT (Diabetes Incidence after REnal Transplantation: Neoral C2 monitoring versus Tacrolimus) inve| | View in PubMed
  147. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus.
    Woodle ES, Vincenti F, Lorber MI, Gritsch HA, Hricik D, Washburn K, Matas AJ, Gallichio M, Neylan J| | View in PubMed
  148. Chronic induction. What's new in the pipeline.
    Vincenti F| | View in PubMed
  149. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen.
    Lipshutz GS, Flechner SM, Govani MV, Vincenti F| | View in PubMed
  150. Interleukin-2 receptor antagonists and aggressive steroid minimization strategies for kidney transplant patients.
    Vincenti F| | View in PubMed
  151. Infliximab in the treatment of steroid-dependent ulcerative colitis.
    Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A| | View in PubMed
  152. A decade of progress in kidney transplantation.
    Vincenti F| | View in PubMed
  153. Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy.
    Ghiggeri GM, Carraro M, Vincenti F| | View in PubMed
  154. Optimizing the use of cyclosporine (Neoral) for recipients of living donor kidneys.
    Vincenti F, Brennan TV, Fuller TF, Feng S| | View in PubMed
  155. Retransplantation in patients with graft loss caused by polyoma virus nephropathy.
    Ramos E, Vincenti F, Lu WX, Shapiro R, Trofe J, Stratta RJ, Jonsson J, Randhawa PS, Drachenberg CB, Papadimitriou JC, Weir MR, Wali RK| | View in PubMed
  156. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
    Pescovitz MD, Bumgardner G, Gaston RS, Kirkman RL, Light S, Patel IH, Nieforth K, Vincenti F| | View in PubMed
  157. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients.
    Posselt AM, Vincenti F, Bedolli M, Lantz M, Roberts JP, Hirose R| | View in PubMed
  158. Immunosuppression minimization: current and future trends in transplant immunosuppression.
    Vincenti F| | View in PubMed
  159. Prevalence and management of anemia in renal transplant recipients: a European survey.
    Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, Eklund B, Kliem V, Legendre C, Morais Sarmento AL, Vincenti F| | View in PubMed
  160. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco.
    Vincenti F, Stock P| | View in PubMed
  161. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil.
    Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A| | View in PubMed
  162. New monoclonal antibodies in renal transplantation.
    Vincenti F| | View in PubMed
  163. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation.
    Vincenti F, Pace D, Birnbaum J, Lantz M| | View in PubMed
  164. What's in the pipeline? New immunosuppressive drugs in transplantation.
    Vincenti F| | View in PubMed
  165. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years.
    Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J| | View in PubMed
  166. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation.
    Parasrampuria DA, Lantz MV, Birnbaum JL, Vincenti FG, Benet LZ| | View in PubMed
  167. Interleukin-2 receptor monoclonal antibodies in renal transplantation: current use and emerging regimens.
    Vincenti F| | View in PubMed
  168. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL, Ramos E, Lin A, Vincenti F, Daclizumab Triple Therapy and Double Therapy Groups| | View in PubMed
  169. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation.
    Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Neylan J, Roza A, Somberg K| | View in PubMed
  170. Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial.
    Vincenti F| | View in PubMed
  171. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F| | View in PubMed
  172. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors.
    Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI, Maia M, Light SE| | View in PubMed
  173. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
    Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL, Stock PG, Hirose R| | View in PubMed
  174. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability.
    Pirsch J, Bekersky I, Vincenti F, Boswell G, Woodle ES, Alak A, Kruelle M, Fass N, Facklam D, Mekki Q| | View in PubMed
  175. The role of daclizumab in balancing resources for inpatient and outpatient transplant services.
    Korsun A, Vincenti F, Ruck D, Whitelaw N, Ladoulis C, Whitelaw G| | View in PubMed
  176. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis.
    Ekberg H, Bäckman L, Tufveson G, Tydén G, Nashan B, Vincenti F| | View in PubMed
  177. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR).
    Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz CJ, Roza AM, Vincenti F, George V| | View in PubMed
  178. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
    Vincenti F| | View in PubMed
  179. Potential of daclizumab in solid organ transplantation.
    Vincenti F| | View in PubMed
  180. Can antibody prophylaxis allow sparing of other immunosuppressives?
    Vincenti F, Grinyo J, Ramos E, Nashan B, Stuart F, Kuypers D, Brattstrom C, Cho S, Ekberg H, Johnson R| | View in PubMed
  181. Recurrent and de novo glomerular disease after renal transplantation: a report from renal allograft disease registry.
    Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz C, Roza AM, Vincenti F, George V| | View in PubMed
  182. Review of transplantation--1999.
    Hirose R, Vincenti F| | View in PubMed
  183. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group.
    Solez K, Vincenti F, Filo RS| | View in PubMed
  184. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
    Vincenti F, Nashan B, Light S| | View in PubMed
  185. Single-center long-term results of renal transplantation for IgA nephropathy.
    Bumgardner GL, Amend WC, Ascher NL, Vincenti FG| | View in PubMed
  186. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J| | View in PubMed
  187. Selection strategies for successful utilization of less than 15.kg pediatric donor kidneys.
    Bretan PN, Freise C, Goldstein R, Osorio R, Tomlanovich S, Amend W, Mathur V, Vincenti F| | View in PubMed
  188. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.
    Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS| | View in PubMed
  189. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group.
    Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS| | View in PubMed
  190. Immunologic and patient selection strategies for successful utilization of less than 15 kg pediatric donor kidneys--long term experiences with 40 transplants.
    Bretan PN, Friese C, Goldstein RB, Osorio RW, Tomlanovich S, Amend W, Mathur V, Vincenti F| | View in PubMed
  191. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation.
    Vincenti F, Lantz M, Birnbaum J, Garovoy M, Mould D, Hakimi J, Nieforth K, Light S| | View in PubMed
  192. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group.
    Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ| | View in PubMed
  193. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group.
    Woodle ES, Thistlethwaite JR, Gordon JH, Laskow D, Deierhoi MH, Burdick J, Pirsch JD, Sollinger H, Vincenti F, Burrows L, Schwartz B, Danovitch GM, Wilkinson AH, Shaffer D, Simpson MA, Freeman RB, Rohrer RJ, Mendez R, Aswad S, Munn SR, Wiesner RH, Delmonico FL, Neylan J, Whelchel J| | View in PubMed
  194. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group.
    Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ| | View in PubMed
  195. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis.
    Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F| | View in PubMed
  196. In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients.
    Stock PG, Lantz M, Light S, Vincenti F| | View in PubMed
  197. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.
    Vincenti F, Danovitch GM, Neylan JF, Steiner RW, Everson MP, Gaston RS| | View in PubMed
  198. Fibrosing cholestatic hepatitis in renal transplant recipients.
    Lam PW, Wachs ME, Somberg KA, Vincenti F, Lake JR, Ferrell LD| | View in PubMed
  199. Histopathological concordance of paired renal allograft biopsy cores. Effect on the diagnosis and management of acute rejection.
    Sorof JM, Vartanian RK, Olson JL, Tomlanovich SJ, Vincenti FG, Amend WJ| | View in PubMed
  200. Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection.
    Orloff SL, Stempel CA, Wright TL, Tomlanovich SJ, Amend WJ, Stock PG, Melzer JS, Vincenti F| | View in PubMed
  201. Phase II FK 506 multicenter concentration control study: one-year follow-up.
    Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A| | View in PubMed
  202. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors.
    Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer JS, Roberts JP, Tomlanovich SJ, Vincenti F| | View in PubMed
  203. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis.
    Artero ML, Sharma R, Savin VJ, Vincenti F| | View in PubMed
  204. Pentoxifylline reduces the first-dose reactions following OKT3.
    Vincenti FG, Vasconcelos M, Birnbaum JL, Tomlanovich SJ, Amend WJ, Melzer JS, Snyder JP| | View in PubMed
  205. Nontransmission of hepatitis C from cadaver kidney donors to transplant recipients.
    Vincenti F, Lake J, Wright T, Kuo G, Weber P, Stempel C| | View in PubMed
  206. Hepatitis C--its prevalence in end-stage renal failure patients and clinical course after kidney transplantation.
    Stempel CA, Lake J, Kuo G, Vincenti F| | View in PubMed
  207. Recurrent focal glomerulosclerosis: natural history and response to therapy.
    Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F| | View in PubMed
  208. Cytokine and T cell receptor gene expression at the site of allograft rejection.
    Krams SM, Falco DA, Villanueva JC, Rabkin J, Tomlanovich SJ, Vincenti F, Amend WJ, Melzer J, Garovoy MR, Roberts JP| | View in PubMed
  209. Hepatitis C virus in cadaver organ donors: prevalence and risk of transmission to transplant recipients.
    Vincenti F, Weber P, Kuo G, Forsell J, Hunt S, Melzer J, Salvatierra O, Stempel C| | View in PubMed
  210. Effect of cyclosporine on the clinical course of HBsAg-positive renal transplant patients.
    Stempel C, Lake J, Ferrell L, Tomlanovich S, Amend W, Salvatierra O, Vincenti F| | View in PubMed
  211. Improved results with combined donor-specific transfusion (DST) and sequential therapy protocol.
    Salvatierra O, McVicar J, Melzer J, Amend W, Vincenti F, Tomlanovich S, Husing R, Rabkin J, Garovoy M| | View in PubMed
  212. Inability of cyclosporine to completely prevent the recurrence of focal glomerulosclerosis after kidney transplantation.
    Vincenti F, Biava C, Tomlanovitch S, Amend WJ, Garovoy M, Melzer J, Feduska N, Salvatierra O| | View in PubMed
  213. Immunologic alterations induced by donor-specific transfusion.
    Lockard-Marduel A, Gumbert M, Tomlanovich S, Amend W, Vincenti F, Schralla P, Melzer J, Feduska NJ, Salvatierra O, Garovoy MR| | View in PubMed
  214. Successful management of the highly sensitized renal allograft recipient.
    Melzer JS, Husing R, Lou C, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Salvatierra O| | View in PubMed
  215. The incidence and impact of herpes simplex virus infections in the first month following renal transplantation.
    Tomlanovich SJ, Sabatte-Caspillo J, Melzer J, Amend W, Vincenti F, Feduska N, Salvatierra O| | View in PubMed
  216. Cyclosporine provides better success rates for both higher- and lower-risk cadaveric kidney transplant recipients.
    Feduska NJ, Melzer JS, Amend WJ, Vincenti F, Tomlanovich SJ, Garovoy M, Husing R, Salvatierra O| | View in PubMed
  217. How to improve results for second renal allografts.
    Melzer JS, Husing RM, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Lou C, Salvatierra O| | View in PubMed
  218. Is cyclosporine effective in preventing recurrence of immune-mediated glomerular disease after renal transplantation?
    Tomlanovich S, Vincenti F, Amend W, Biava C, Melzer J, Feduska N, Salvatierra O| | View in PubMed
  219. Posttransplant renal rejection: comparison of quantitative scintigraphy, US, and MR imaging.
    Hricak H, Terrier F, Marotti M, Engelstad BL, Filly RA, Vincenti F, Duca RM, Bretan PN, Higgins CB, Feduska N| | View in PubMed
  220. Donor-specific blood transfusions versus cyclosporine--the DST story.
    Salvatierra O, Melzer J, Vincenti F, Amend WJ, Tomlanovich S, Potter D, Husing R, Garovoy M, Feduska NJ| | View in PubMed
  221. Has cyclosporine really relegated pretransplant blood transfusions to therapeutic obsolescence?
    Melzer JS, Husing RM, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Salvatierra O| | View in PubMed
  222. Observations relating to the incidence of the acquired immune deficiency syndrome and other possibly associated conditions in a large population of renal transplant recipients.
    Feduska NJ, Perkins HA, Melzer J, Amend WJ, Vincenti F, Tomlanovich S, Garovoy M, Salvatierra O| | View in PubMed
  223. Sonography in the diagnosis of acute renal allograft rejection and cyclosporine nephrotoxicity.
    Linkowski GD, Warvariv V, Filly RA, Vincenti F| | View in PubMed
  224. The beneficial effect of pretransplant blood transfusions in cyclosporine-treated cadaver renal allograft recipients.
    Melzer JS, Husing RM, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Salvatierra O| | View in PubMed
  225. Renal allograft rejection: US evaluation.
    Hoddick W, Filly RA, Backman U, Callen PW, Vincenti F, Hricak H, Mahony BS, Amend W| | View in PubMed
  226. The clinical course of IgA-nephropathy and Henoch-Schönlein purpura following renal transplantation.
    Bachman U, Biava C, Amend W, Feduska N, Melzer J, Salvatierra O, Vincenti F| | View in PubMed
  227. Clinical management of immunosuppressive therapy for cyclosporine-treated recipients of cadaver kidney transplants at one to six months.
    Feduska NJ, Melzer J, Amend WJ, Vincenti F, Tomlanovich S, Salvatierra O| | View in PubMed
  228. Is a "low" dose of prednisone better than a "high" dose at the time of renal transplantation?
    Stabile C, Vincenti F, Garovoy M, Duca R, Melzer J, Feduska NJ, Salvatierra O, Amend WJ| | View in PubMed
  229. A seven-year experience with donor-specific blood transfusions. Results and considerations for maximum efficacy.
    Salvatierra O, Melzer J, Potter D, Garovoy M, Vincenti F, Amend WJ, Husing R, Hopper S, Feduska NJ| | View in PubMed
  230. Pharmacokinetics of sulfisoxazole in renal transplant patients.
    Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S| | View in PubMed
  231. Dramatic improvement in the success rate for renal transplants in diabetic recipients with donor-specific transfusions.
    Feduska NJ, Melzer J, Amend W, Vincenti F, Duca R, Garovoy M, Hopper S, Salvatierra O| | View in PubMed
  232. Peptic ulcer disease in kidney transplant recipients.
    Feduska NJ, Amend WJ, Vincenti F, Melzer JS, Duca R, Garovoy MR, Salvatierra O| | View in PubMed
  233. Parathyroid and bone response of the diabetic patient to uremia.
    Vincenti F, Arnaud SB, Recker R, Genant H, Amend WJ, Feduska NJ, Salvatierra O| | View in PubMed
  234. Long-term renal function in kidney donors. Sustained compensatory hyperfiltration with no adverse effects.
    Vincenti F, Amend WJ, Kaysen G, Feduska N, Birnbaum J, Duca R, Salvatierra O| | View in PubMed
  235. The role of blood transfusions in renal transplantation.
    Salvatierra O, Vincenti F, Amend WJ, Garovoy MR, Potter D, Feduska NJ| | View in PubMed
  236. De novo and recurrent membranous glomerulopathy following kidney transplantation.
    Berger BE, Vincenti F, Biava C, Amend WJ, Feduska N, Salvatierra O| | View in PubMed
  237. Furosemide assays and disposition in healthy volunteers and renal transplant patients.
    Benet LZ, Smith DE, Lin ET, Vincenti F, Gambertoglio JG| | View in PubMed
  238. Urinary kallikrein excretion after renal transplantation: relationship to hypertension, graft source, and renal function.
    O'Connor DT, Barg AP, Amend W, Vincenti F| | View in PubMed
  239. Blood transfusions before and on the day of transplantation: effects on cadaver graft survival.
    Feduska NJ, Amend WJ, Vincenti F, Duca R, Salvatierra O| | View in PubMed
  240. Update of the University of California at San Francisco experience with donor-specific blood transfusions.
    Salvatierra O, Iwaki Y, Vincenti F, Amend W, Terasaki P, Garovoy M, Duca R, Hopper S, Feduska N| | View in PubMed
  241. Blood transfusions and kidney transplantation.
    Vincenti F, Amend WJ, Feduska NJ, Salvatierra O| | View in PubMed
  242. Prednisone and prednisolone bioavailability in renal transplant patients.
    Gambertoglio JG, Frey FJ, Holford NH, Birnbaum JL, Lizak PS, Vincenti F, Feduska NJ, Salvatierra O, Amend WJ| | View in PubMed
  243. Prognostic features of early renal transplant rejections.
    Amend WJ, Vincenti F, Duca R, Feduska NJ, Cochrum K, Potter D, Salvatierra O| | View in PubMed
  244. Septic arthritis following renal transplantation.
    Vincenti F, Amend WJ, Feduska NJ, Salvatierra O| | View in PubMed
  245. An alternative to cadaver kidney transplants for patients with insulin-dependent diabetes mellitus.
    Feduska NJ, Vincenti F, Amend W, Iwaki Y, Opelz G, Terasaki P, Duca R, Hopper S, Salvatierra O| | View in PubMed
  246. Incidence, characteristics, and outcome of recipients sensitized after donor-specific blood transfusions.
    Salvatierra O, Iwaki Y, Vincenti F, Amend W, Potter D, Opelz G, Terasaki P, Duca R, Hopper S, Feduska N| | View in PubMed
  247. Improved graft survival following donor-specific blood transfusions.
    Cochrum K, Hanes D, Potter D, Perkins H, Amend W, Vincenti F, Iwaki Y, Opelz G, Terasaki P, Levin B, Sampson D, Feduska N, Salvatierra O| | View in PubMed
  248. Prevention of prednisone-induced negative nitrogen balance. Effect of dietary modification on urea generation rate in patients on hemodialysis receiving high-dose glucocorticoids.
    Cogan MG, Sargent JA, Yarbrough SG, Vincenti F, Amend WJ| | View in PubMed
  249. 1,500 renal transplants at one center: evolution of a strategy for optimal success.
    Salvatierra O, Amend W, Vincenti F, Potter D, Stoney R, Duca R, Feduska N| | View in PubMed
  250. Furosemide kinetics and dynamics after kidney transplant.
    Smith DE, Gambertoglio JG, Vincenti F, Benet LZ| | View in PubMed
  251. Recurrent systemic lupus erythematosus involving renal allografts.
    Amend WJ, Vincenti F, Feduska NJ, Salvatierra O, Johnston WH, Jackson J, Tilney N, Garovoy M, Burwell EL| | View in PubMed
  252. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis.
    Vincenti F, Hattner R, Amend WJ, Feduska NJ, Duca RM, Salvatierra O| | View in PubMed
  253. Graft survival with high levels of cytotoxic antibodies.
    Feduska NJ, Amend WJ, Vincenti F, Perkins HA, Opelz G, Terasaki PI, Iwaki Y, Duca R, Dodge D, Salvatierra O| | View in PubMed
  254. Improved graft survival with donor-specific transfusion pretreatment.
    Cochrum K, Hanes D, Potter D, Perkins H, Amend W, Vincenti F, Iwaki Y, Opelz G, Terasaki P, Feduska N, Salvatierra O| | View in PubMed
  255. Pretreatment with donor-specific blood transfusions in related recipients with high MLC.
    Salvatierra O, Amend W, Vincenti F, Potter D, Iwaki Y, Opelz G, Terasaki P, Duca R, Hanes D, Cochrum KC, Hopper S, Feduska NJ| | View in PubMed
  256. Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients.
    Gambertoglio JG, Vincenti F, Feduska NJ, Birnbaum J, Salvatierra O, Amend WJ| | View in PubMed
  257. Improved outcome following renal transplantation with reduction in the immunosuppression therapy for rejection episodes.
    Vincenti F, Amend W, Feduska NJ, Duca RM, Salvatierra O| | View in PubMed
  258. The role of hypertension in hemodialysis-associated atherosclerosis.
    Vincenti F, Amend WJ, Abele J, Feduska NJ, Salvatierra O| | View in PubMed
  259. Post-transplantation pyelonephritis: factors producing low patient and transplant morbidity.
    Pearson JC, Amend WJ, Vincenti FG, Feduska NJ, Salvatierra O| | View in PubMed
  260. Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach.
    Salvatierra O, Vincenti F, Amend W, Potter D, Iwaki Y, Opelz G, Terasaki P, Duca R, Cochrum K, Hanes D, Stoney RJ, Feduska NJ| | View in PubMed
  261. The organization of a successful donor-specific transfusion protocol in related recipients with high MLC.
    Hopper S, Feduska N, Vincenti F, Amend W, Salvatierra O| | View in PubMed
  262. Donor-specific blood transfusions in HLA-D-disparate one-haplotype-related allografts.
    Cochrum KC, Hanes D, Potter D, Vincenti F, Amend W, Feduska N, Perkins H, Salvatierra O| | View in PubMed
  263. Results and significance of angiography in potential kidney donors.
    Spring DB, Salvatierra O, Palubinskas AJ, Amend WJ, Vincenti FG, Feduska NJ| | View in PubMed
  264. The transplanted kidney as a source of hepatitis B infection.
    Wolf JL, Perkins HA, Schreeder MT, Vincenti F| | View in PubMed
  265. Analysis of costs and outcomes of renal transplantation at one center. Its implications.
    Salvatierra O, Feduska NJ, Vincenti F, Duca R, Potter D, Nolan J, Cochrum KC, Amend WJ| | View in PubMed
  266. Comparative study of albumin solution and cryoprecipitated plasma for renal preservation: a preliminary report.
    Feduska NJ, Collins GM, Amend WJ, Vincenti F, Duca RM, Stieper KW, Mitchell JW, Cochrum KC, Salvatierra O| | View in PubMed
  267. HLA-D antigen disparity and HLA-DRw antibodies in intrafamilial renal allograft survival.
    Cochrum K, Hanes D, Van Speybroeck J, Perkins H, Ferrone S, Indeveri F, Amend W, Vincenti F, Feduska N, Salvatierra O| | View in PubMed
  268. The influence of donor age on graft survival.
    Speybroeck JV, Feduska N, Amend W, Vincenti F, Cochrum K, Salvatierra O| | View in PubMed
  269. Do blood transfusions enhance the possibility of a compatible transplant?
    Feduska NJ, Vincenti F, Amend WJ, Duca R, Cochrum K, Salvatierra O| | View in PubMed
  270. Pretransplant cytotoxic antibodies do not segregate kidney transplant recipients into responder and non-responder groups.
    Vincenti F, Amend W, Feduska N, Duca R, Salvatierra O| | View in PubMed
  271. Immunologic factors determining survival of cadaver-kidney transplants. The effect of HLA serotyping, cytotoxic antibodies and blood transfusions on graft survival.
    Vincenti F, Duca RM, Amend W, Perkins HA, Cochrum KC, Feduska NJ, Salvatierra O| | View in PubMed
  272. Leukocyte migration inhibitory factor (LIF) as an indicator of presensitization and allograft survival.
    Cochrum KC, Haynes DM, Salvatierra O, Feduska NJ, Vincenti F, Van Speybroeck J| | View in PubMed
  273. The effect of hypothermic pulsatile perfusion on glomerular epithelial surface structures studied by scanning electron microscopy.
    Vincenti F, Amend W, Feduska N, Maglio M, Axel L, Cochrum K, Salvatierra O| | View in PubMed
  274. Hepatitis-B reactivation after renal transplantation.
    Denes AE, Berquist KR, Fields HA, Vincenti F| | View in PubMed
  275. Renal vein renin in hypertension. Diagnostic and therapeutic implications.
    Vincenti F, Birbari A, Rizk G| | View in PubMed
  276. Tumorous hyperparathyroidism in hypophosphatemic vitamin D--resistant rickets.
    Vincenti F, Hajjar ET, Salti IS| | View in PubMed